Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : SVB Leerink Adjusts Pfizer PT to $50 From $49, Maintains Market Perform Rating

09/20/2021 | 08:10am EST


ę MT Newswires 2021
All news about PFIZER, INC.
11/26ADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
11/26US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New COVID-19 Stra..
MT
11/26CLOSE UPDATE : US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New C..
MT
11/26FTSE 100 Closes Friday Down as Latest Coronavirus Variant Sparks Sell-off
DJ
11/26Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
DJ
11/26New purchase in the MarketScreener USA Portfolio
11/26FDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
11/26Pfizer Up Over 6%, on Track for Record High Close -- Data Talk
DJ
11/26New Analysis Shows Merck COVID-19 Pill Molnupiravir Less Effective Than Previously Repo..
MT
11/26Health Care Stocks Mixed Pre-Bell Friday
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 529 M - -
Net income 2021 21 354 M - -
Net Debt 2021 27 827 M - -
P/E ratio 2021 13,9x
Yield 2021 2,92%
Capitalization 303 B 303 B -
EV / Sales 2021 4,06x
EV / Sales 2022 3,97x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 54,00 $
Average target price 48,53 $
Spread / Average Target -10,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.46.70%303 095
JOHNSON & JOHNSON1.82%421 847
ROCHE HOLDING AG17.17%334 769
NOVO NORDISK A/S68.76%247 704
ELI LILLY AND COMPANY55.18%237 527
ABBVIE INC.10.74%209 777